Leiguang Ye

951 total citations
18 papers, 631 citations indexed

About

Leiguang Ye is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Leiguang Ye has authored 18 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Leiguang Ye's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer-related molecular mechanisms research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Leiguang Ye is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer-related molecular mechanisms research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Leiguang Ye collaborates with scholars based in China, United States and United Kingdom. Leiguang Ye's co-authors include Baogang Liu, Meisi Yan, Te‐Chun Hsia, Shu‐Fen Chiang, Fang� Yang, Shao‐Chun Wang, Jennifer L. Hsu, Gabriel N. Hortobágyi, Ying‐Nai Wang and Heng‐Huan Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Oncogene.

In The Last Decade

Leiguang Ye

17 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leiguang Ye China 11 382 228 199 187 94 18 631
Xueqing Yao China 13 360 0.9× 210 0.9× 118 0.6× 230 1.2× 103 1.1× 51 635
Parunya Chaiyawat Thailand 17 457 1.2× 137 0.6× 158 0.8× 187 1.0× 125 1.3× 40 653
Svasti Haricharan United States 14 359 0.9× 399 1.8× 107 0.5× 220 1.2× 152 1.6× 24 754
Xin Jing China 12 305 0.8× 173 0.8× 135 0.7× 106 0.6× 56 0.6× 28 554
Galina M. Kiriakova United States 10 380 1.0× 310 1.4× 169 0.8× 210 1.1× 56 0.6× 11 707
Sonia H.Y. Kung Canada 10 280 0.7× 235 1.0× 202 1.0× 141 0.8× 161 1.7× 23 616
Jinxue Zhou China 16 326 0.9× 271 1.2× 274 1.4× 220 1.2× 94 1.0× 32 744
Henrique O. Duarte Portugal 11 317 0.8× 101 0.4× 139 0.7× 91 0.5× 43 0.5× 23 454
Atsuko Ashida Japan 11 330 0.9× 317 1.4× 184 0.9× 139 0.7× 53 0.6× 29 636
Lucas Fass United States 3 208 0.5× 126 0.6× 100 0.5× 95 0.5× 55 0.6× 9 446

Countries citing papers authored by Leiguang Ye

Since Specialization
Citations

This map shows the geographic impact of Leiguang Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leiguang Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leiguang Ye more than expected).

Fields of papers citing papers by Leiguang Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leiguang Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leiguang Ye. The network helps show where Leiguang Ye may publish in the future.

Co-authorship network of co-authors of Leiguang Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Leiguang Ye. A scholar is included among the top collaborators of Leiguang Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leiguang Ye. Leiguang Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Ye, Leiguang, et al.. (2025). Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance. Journal of Nanobiotechnology. 23(1). 722–722. 1 indexed citations
3.
Yu, Jinming, Anthony W. Tolcher, Costantine Albany, et al.. (2024). A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14504–e14504. 3 indexed citations
4.
Li, Xuemeng, Fang� Yang, Baogang Liu, et al.. (2024). Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor–Associated Pneumonitis in Patients With Lung Cancer. Journal of Immunotherapy. 47(6). 220–226. 2 indexed citations
5.
Chen, Chen, Leiguang Ye, Jinfeng Yi, Liu Tang, & Zhigao Li. (2023). FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer. Breast Cancer Research and Treatment. 201(3). 515–533. 12 indexed citations
6.
Ye, Leiguang, Yingpu Li, Sifan Zhang, Jinsong Wang, & Bo Lei. (2023). Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression. Cytokine & Growth Factor Reviews. 73. 27–39. 39 indexed citations
7.
Liu, Jianyu, Bo Lei, Xin Yu, et al.. (2022). Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer. Frontiers in Immunology. 13. 888339–888339. 4 indexed citations
8.
Jiang, Ke, Peng Liu, Dapeng Liang, et al.. (2020). SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis. Oncogene. 39(27). 5015–5030. 20 indexed citations
9.
Yang, Fang�, Yubo Yan, Yang� Yang, et al.. (2020). MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cellular Signalling. 73. 109675–109675. 82 indexed citations
10.
Yan, Meisi, Leiguang Ye, Xinxin Feng, et al.. (2020). MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.. PubMed. 10(3). 965–974. 18 indexed citations
11.
Lee, Heng‐Huan, Ying‐Nai Wang, Weiya Xia, et al.. (2019). Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 36(2). 168–178.e4. 282 indexed citations
12.
Zhang, Xu, Teng Yang, Fang� Yang, et al.. (2015). MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncology Reports. 33(5). 2599–2605. 45 indexed citations
13.
Ye, Leiguang, Hui Wang, & Baogang Liu. (2015). miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumor Biology. 37(1). 1151–1157. 35 indexed citations
14.
Ye, Leiguang, et al.. (2015). Study of circulating IgG antibodies to BIRC5 and MYC in non‐small cell lung cancer. FEBS Open Bio. 5(1). 809–812. 7 indexed citations
15.
Ye, Leiguang, et al.. (2013). Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumor Biology. 34(3). 1873–1877. 23 indexed citations
16.
Zhang, Cong, Leiguang Ye, Shunzi Jin, et al.. (2013). Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumor Biology. 35(3). 2047–2051. 21 indexed citations
17.
Wang, Weili, Leiguang Ye, Xiaomei Li, et al.. (2013). Circulating IgG antibody against FOXP3 may be a potential biomarker for lung cancer. 2(4). 79–83. 3 indexed citations
18.
Liu, Tong, Leiguang Ye, Xiaoshuan Liang, et al.. (2012). Immunopontentiating and antitumor activities of a polysaccharide from Pulsatilla chinensis (Bunge) Regel. International Journal of Biological Macromolecules. 54. 225–229. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xueqing Yao Breakdown of academic impact, for papers by Parunya Chaiyawat Breakdown of academic impact, for papers by Svasti Haricharan Breakdown of academic impact, for papers by Xin Jing Breakdown of academic impact, for papers by Galina M. Kiriakova Breakdown of academic impact, for papers by Sonia H.Y. Kung Breakdown of academic impact, for papers by Jinxue Zhou Breakdown of academic impact, for papers by Henrique O. Duarte Breakdown of academic impact, for papers by Atsuko Ashida Breakdown of academic impact, for papers by Lucas Fass
Rankless by CCL
2026